Lodoxamide
Подписчиков: 0, рейтинг: 0
|
| |
| Names | |
|---|---|
|
Preferred IUPAC name
N,N′-(2-Chloro-5-cyano-1,3-phenylene)dioxamic acid | |
| Identifiers | |
|
3D model (JSmol)
|
|
| ChEMBL | |
| ChemSpider |
|
|
PubChem CID
|
|
| UNII | |
|
CompTox Dashboard (EPA)
|
|
| |
| |
| Properties | |
| C11H6ClN3O6 | |
| Molar mass | 311.63 g·mol−1 |
| Pharmacology | |
| S01GX05 (WHO) | |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Lodoxamide is an antiallergic pharmaceutical drug. It is marketed under the tradename Alomide in the UK. Like cromoglicic acid it acts as a mast cell stabilizer. In 2014 lodoxamide and bufrolin were found to be potent agonists at the G protein-coupled receptor 35, an orphan receptor believed to play a role in inflammatory processes, pain and the development of stomach cancer.